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Angiogenesis, the formation of new blood vessels from existing vasculature, is important
in tumor growth and metastasis. A key regulator of angiogenesis is vascular endothelial
growth factor (VEGF), which has been targeted in numerous anti-angiogenic therapies
aimed at inhibiting tumor angiogenesis. Systems biology approaches, including compu-
tational modeling, are useful for understanding this complex biological process and can
aid in the development of novel and effective therapeutics that target the VEGF family
of proteins and receptors. We have developed a computational model of VEGF transport
and kinetics in the tumor-bearing mouse, which includes three-compartments: normal tis-
sue, blood, and tumor. The model simulates human tumor xenografts and includes human
(VEGF121 and VEGF165) and mouse (VEGF120 and VEGF164) isoforms. The model incorpo-
rates molecular interactions between these VEGF isoforms and receptors (VEGFR1 and
VEGFR2), as well as co-receptors (NRP1 and NRP2). We also include important soluble
factors: soluble VEGFR1 (sFlt-1) and α-2-macroglobulin. The model accounts for transport
via macromolecular transendothelial permeability, lymphatic flow, and plasma clearance.
We have fit the model to available in vivo experimental data on the plasma concentration
of free VEGF Trap and VEGF Trap bound to mouse and human VEGF in order to esti-
mate the rates at which parenchymal cells (myocytes and tumor cells) and endothelial
cells secrete VEGF. Interestingly, the predicted tumor VEGF secretion rates are signifi-
cantly lower (0.007–0.023 molecules/cell/s, depending on the tumor microenvironment)
than most reported in vitro measurements (0.03–2.65 molecules/cell/s). The optimized
model is used to investigate the interstitial and plasma VEGF concentrations and the effect
of theVEGF-neutralizing agent,VEGFTrap (aflibercept).This work complements experimen-
tal studies performed in mice and provides a framework with which to examine the effects
of anti-VEGF agents, aiding in the optimization of such anti-angiogenic therapeutics as
well as analysis of clinical data.The model predictions also have implications for biomarker
discovery with anti-angiogenic therapies.
Keywords: systems biology, mathematical model, computational model, angiogenesis, tumor xenograft model,
anti-angiogenic therapy, cancer
INTRODUCTION
Angiogenesis is the formation of new blood capillaries from pre-
existing vessels, and is a process involved in physiological function,
such as exercise and wound healing, as well as disease conditions,
including cancer, peripheral and coronary artery diseases, pre-
eclampsia, and age-related macular degeneration (AMD). The
vascular endothelial growth factor (VEGF) family is a key pro-
moter of angiogenesis and vascular development. The VEGF fam-
ily includes five ligands: VEGF-A,VEGF-B,VEGF-C,VEGF-D, and
placental growth factor (PlGF). One of the most widely studied
members is VEGF-A, commonly referred to as VEGF. Alternative
splicing of VEGF produces different isoforms, including VEGF121,
VEGF165, VEGF189, and VEGF206 in humans. Expressed rodent
isoforms are one amino acid shorter than human isoforms; there-
fore, the subscripted number is one less. Additionally, there are
VEGFxxxb isoforms, which have been shown to be endogenous
anti-angiogenic species (1, 2). VEGF promotes angiogenesis by
binding to and activating its receptors VEGFR1 and VEGFR2,
and co-receptors called neuropilins (NRPs). Signal transduction
through the receptors promotes many cellular processes, includ-
ing cell proliferation, migration, and survival (3). VEGFR1 and
VEGFR2 are expressed on endothelial cells (ECs), cancer cells, and
other cell types, including bone marrow-derived cells and neu-
rons [see (4) for review]. NRPs are expressed on various cell types,
including ECs, tumor cells, and muscle fibers (4).
Angiogenesis has been targeted to treat diseases character-
ized by reduced vascularization (“pro-angiogenic therapy”) (5, 6)
or to inhibit the formation of new blood vessels in conditions
leading to hypervascularization (“anti-angiogenic therapy”) (7,
8). Of particular importance is anti-angiogenic therapy targeting
tumor vascularization. Bevacizumab (9) is a recombinant mon-
oclonal antibody that neutralizes VEGF and is approved by the
Food and Drug Administration to treat colorectal cancer, glioblas-
toma, kidney cancer, and non-small cell lung cancer. Aflibercept
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(Regeneron) is a soluble decoy receptor approved to treat metasta-
tic colorectal cancer and wet AMD. The drug is also in clinical trials
to evaluate its anti-angiogenic effect on various forms of cancers
(10). Aflibercept binds to VEGF more tightly than bevacizumab
(11) and forms a 1:1 complex with VEGF and PlGF (12). In addi-
tion to therapies that target the VEGF ligand, several tyrosine
kinase inhibitors (TKIs) have been developed to target phosphory-
lation of VEGF receptors, as well as other pro-angiogenic receptors
including platelet-derived growth factor (PDGF) receptors and
fibroblast growth factor (FGF) receptors (13, 14).
Systems biology approaches, including quantitative experimen-
tal methods and mathematical modeling, have been applied to
study angiogenesis (15–17). Computational models complement
experimental studies and can aid in the development and opti-
mization of effective therapeutics (18). Despite extensive basic
science and translational research to develop anti-angiogenic ther-
apies, little is known about the drugs’ mechanism of action, how
and why tumors become resistant to the treatment, or the patient
population that can benefit most from these drugs. Identifying bio-
markers that can be used to predict the patients whose tumors will
respond favorably to anti-angiogenic treatment is of great inter-
est (19–21). Computational approaches can shed light upon these
issues by providing a framework to generate and test hypotheses
related to VEGF kinetics and transport in the body (14, 22).
We have previously developed an experiment-based compart-
ment model of VEGF distribution in non-tumor-bearing mice,
which estimates the distribution of VEGF in the body (23). Addi-
tionally, the model was used to fit kinetic parameters and to
predict the rate at which VEGF is secreted by muscle fibers,
which is difficult to measure experimentally in vivo. In this work,
we present an expanded model that includes a tumor compart-
ment and incorporates several new features: EC secretion of
VEGF, soluble factors that influence VEGF levels, and a dynamic
tumor volume. These new elements lead to a more physiolog-
ical model and incorporate experimental observations relevant
to VEGF kinetics and transport in the whole body, which can
be compared to experimental data. Thus, this work represents a
significant expansion to our previous models (23–26). We first
re-calibrate the two-compartment model (no tumor is present)
using in vivo experimental data and estimate the rates at which
VEGF is secreted by muscle fibers and ECs, as well as the clearance
rates of unbound and complexed VEGF Trap, and the bind-
ing affinity of VEGF trap. We then fit the three-compartment
model to available in vivo experimental data in order to esti-
mate the rate of VEGF secretion by muscle fibers, ECs, and tumor
cells. We demonstrate how the model can be applied to inves-
tigate the effect of neutralizing VEGF using VEGF Trap. These
results contribute to our understanding of the efficacy of VEGF
Trap in specific tumor types. We also estimate the concentra-
tions of VEGF in different compartments, which can be validated
experimentally.
RESULTS
RE-CALIBRATION OF TWO-COMPARTMENT MODEL CAPTURES
DYNAMICS OF BOUND AND COMPLEXED VEGF TRAP
The previous two-compartment model simulating non-tumor-
bearing mice (23) did not include EC secretion of VEGF or soluble
factors. Therefore, we first refit the expanded two-compartment
model that includes these additional features in order to match
in vivo experimental data (12). The fitting optimized the val-
ues of five parameters: VEGF secretion rate of muscle fibers
(qmuscleVEGF ), VEGF secretion rate of ECs (q
EC
VEGF), clearance rate of
VEGF Trap (cA), clearance rate of the VEGF/VEGF Trap complex
(cVA), and dissociation constant of VEGF and VEGF Trap (K d).
As described in the methods, although the experimental protocol
used by Rudge and coworkers utilizes subcutaneous administra-
tion of VEGF Trap, we simulate intravenous administration and
assume 100% of the reported dose is administered. The fitting
procedure allows us to estimate the values of the free parameters
using in vivo experimental data.
The optimized parameter values are shown in Table 1, and
all raw data from the optimization is given in File 1 in Supple-
mentary Material. The optimized value of K d is comparable to
the reported in vitro measurement of 0.6 pM (11), providing con-
fidence in the fitting procedure. The optimization predicts the
muscle fibers secrete very little VEGF (0.002 molecules/cell/s), and
the standard deviation of the optimized values is high. This sug-
gests that the model is not sensitive to the value of (qmuscleVEGF ).
To investigate this possibility, we varied muscle secretion from
0 to 0.02 molecules/cell/s and used the model to estimate the
concentrations of unbound VEGF Trap and the mouse VEGF
(mVEGF)/VEGF Trap complex. This sensitivity study revealed
that increasing (qmuscleVEGF ) up to one order of magnitude does
not significantly change the fit, as shown in Figure 1. These
results indicate that there may not be sufficient data to deter-
mine VEGF secretion from muscle fibers. Specifically, it is dif-
ficult to separate the contribution of VEGF from muscle fibers,
compared to ECs. This result is not specific to the data used
here, but more generally that plasma measurements cannot be
used to determine endogenous VEGF production from multiple
sources.
SENSITIVITY ANALYSIS REVEALS MODEL PARAMETERS THAT
INFLUENCE VEGF CONCENTRATIONS
In the three-compartment model, the values of several parame-
ters are based on characterization of the human VEGF (hVEGF)
system due to a lack of quantitative experimental measurements
in mice. We previously investigated sensitivity to individual para-
meters, including vascular permeability, lymphatic drainage, and
properties of the anti-VEGF agent (25). In that work, parameters






Normal secretion Molecules/cell/s 0.002 0.003
EC secretion Molecules/cell/s 0.057 0.004
Tumor secretion Molecules/cell/s N/A N/A
Clearance of free VEGF Trap s−1 1.3×10−5 2×10−7
Clearance of bound VEGF
Trap
s−1 2.5×10−6 2×10−7
K d of VEGF Trap pM 0.29 0.011
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FIGURE 1 | Effect of varying muscle secretion in two-compartment
model. The estimated plasma levels of free VEGF Trap (dashed lines) and
mouse VEGF bound to VEGF Trap (solid lines) after a single intravenous
injection of VEGF Trap at (A), 0.5 mg/kg; (B), 2.5 mg/kg; (C), 10 mg/kg; and (D),
25 mg/kg. The rate of VEGF secretion by muscle fibers is varied from 0 to
0.02 molecules/cell/s. Model results are compared to experimental
measurements for free VEGF Trap (black circles) and mVEGF bound to VEGF
Trap (white squares).
were varied one by one. Here, we perform a modular sensitiv-
ity analysis, where we investigate how variability in three sets of
parameters (model inputs) influence mouse and hVEGF concen-
trations and sVEGFR1 levels in normal tissue, blood, and tumor
(model outputs). Specifically, we investigated the effect of VEGF
receptor expression, transport parameters, and kinetic parameters
using the extended Fourier Amplitude Sensitivity Test (eFAST),
as described in the Section “Materials and Methods.” Two indices
provide an estimate of the sensitivity of the model output to model
parameters. The first FAST index quantifies the variance of a model
output with respect to the variance of each input. The total FAST
index quantifies the variance of a model output with respect to
the variances of each input and covariances between all combi-
nations of inputs. If total FAST indices are larger than the first
FAST indices, it means that the parameter is more important in
combination with other parameters rather than individually.
The FAST indices for each set of model inputs are shown in
Figure 2. When investigating the effect of tumor cell receptor
expression,VEGF and sVEGFR1 concentrations are sensitive to the
density of NRP co-receptors. Additionally, the level of VEGFR1 is
an important determinant of hVEGF concentration in the tumor.
In the transport module, the rate of lymphatic flow from normal
or tumor tissue in concert with other transport parameters is esti-
mated to influence hVEGF levels in plasma and normal tissue. Sol-
uble VEGFR1 concentrations, as well as mVEGF levels in plasma
and normal tissue, are particularly sensitive to the permeability of
the normal tissue to VEGF and VEGF/sVEGFR1 complexes. Indi-
vidual parameters investigated in the kinetic module are predicted
to influence VEGF and sVEGFR1 concentrations, rather than in
combination with other kinetic parameters. VEGF and sVEGFR1
levels are particularly sensitive to VEGF164 and VEGF165 binding
to NRP co-receptors and VEGF binding to VEGFR1. These results
aid in our understanding of how uncertainty in the values of par-
ticular parameters influence the model output. Additionally, the
sensitivity analysis provides quantitative data to support obtaining
additional experimental measurements of specific parameters that
significantly influence model outputs.
THE RATE OF VEGF SECRETION BY HUMAN TUMOR CELLS IS
DEPENDENT ON THE TUMOR MICROENVIRONMENT
Tumor cells are a source of VEGF; however, there is a lack of in vivo
data for VEGF secretion rates. Therefore, we have used in vivo
experimental data on the plasma concentration of free VEGF Trap
and VEGF Trap bound to mouse and hVEGF to determine VEGF
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FIGURE 2 | Sensitivity indices of model parameters. The extended Fourier
Amplitude Sensitivity Test (eFAST) was used to estimate the variance in the
model output with respect with variance in individual model inputs (first FAST
indices) and covariances in combinations of model inputs (total FAST indices).
A modular approach was used to investigate the sensitivity to (A), tumor
receptor expression; (B), transport parameters; and (C), kinetic parameters.
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secretion rates in mice bearing human tumor xenografts. Here,
we use the clearance rates of unbound and complexed VEGF
Trap predicted in the two-compartment model and experimentally
determined VEGF binding affinity. However, the VEGF secretion
rates (qmuscleVEGF ,q
EC
VEGF, and tumorVEGF secretion,q
tumor
VEGF ) were opti-
mized to fit experimental data. We optimize the VEGF secretion
rates since there is large variability in the predicted rate of muscle
secretion obtained using the two-compartment model.
The VEGF secretion rates were predicted using the optimiza-
tion algorithm, assuming the tumors follow either the average
(baseline) or fast tumor growth profiles. We use data from Rudge
et al. (12), where tumors were allowed to grow to ∼100 mm3,
and then the tumor-bearing mice were injected with VEGF Trap
(“anti-VEGF”) twice weekly for 2 weeks. Various dosages of VEGF
Trap were used, and the concentrations of free VEGF Trap and
the mVEGF/VEGF Trap complex and hVEGF/VEGF Trap com-
plex in the blood were measured. These measurements can be
directly compared to model estimates where the anti-VEGF agent
is administered intravenously. The optimized model provides a
good fit to the experimental data, as shown in Figure 3. The
average and standard deviation of the predicted VEGF secre-
tion rates from the optimization runs are in Figure 4 and
Table 2, and File 1 in Supplementary Material contains the
raw data.
CIRCULATING LEVELS OF VEGF TRAP AND HUMAN VEGF/VEGF TRAP
COMPLEX AND MAXIMUM CONCENTRATION OF TOTAL VEGF TRAP
VARY WITH DOSE
To our knowledge, the dynamic levels of free and complexed VEGF
Trap in tumor-bearing mice have not been reported. These data are
useful in elucidating the mechanism of action of VEGF Trap and
to determine if the dosage is sufficient to neutralize VEGF secreted
by the tumor. Therefore, we used the optimized model for A673
rhabdomyosarcoma human xenograft to predict the concentra-
tion profiles for free VEGF Trap and VEGF Trap bound to hVEGF
(Figure 5). The level of VEGF Trap bound to hVEGF is more than
an order of magnitude lower than the concentration of mVEGF
complexed with VEGF Trap. This result is consistent with the find-
ing that normal production of VEGF eclipses the production from
tumors, as described by Rudge and co-authors (12). Addition-
ally, the level of free VEGF Trap remains well above the level of
the hVEGF/VEGF trap complex for up to 14 days. This indicates
effective dosing, as the VEGF-neutralizing agent is able to neu-
tralize all VEGF secreted by the tumor. The HT1080 fibrosarcoma
tumor response is similar (data not shown).
VEGF TRAP IS PREDICTED TO DEPLETE UNBOUND VEGF IN THE BODY
The optimized model of a tumor-bearing mouse provides a
framework with which to study the concentration of unbound
VEGF before and after administration of VEGF Trap. As expected,
endogenous levels of unbound VEGF are highest in the normal
tissue and plasma, and the concentration of hVEGF is highest
in the tumor, based on the source of mouse and hVEGF. Before
any injection, mVEGF concentration is estimated to range from
0.17 to 1.47 pM in mice with A673 tumors, based on 1 SD above
and below the average predicted VEGF secretion rates (Table 3).
Unbound hVEGF in the tumor is estimated to be∼0.5 pM. We also
FIGURE 3 | Predicted systemic VEGFTrap levels. The model predicts the
plasma levels of free VEGF Trap (black lines), mouse VEGF bound to VEGF
Trap (blue lines), and human VEGF bound to VEGF Trap (red lines). VEGF Trap
was administered twice per week for 2 weeks at doses of 0.5, 1, 2.5, 10,
and 25 mg/kg. The simulated results are shown for the optimized model
where the secretion rates of VEGF by myocytes, EC, and tumor cells were
fit to experimental data (circles). We use the mean (solid lines) and 1 SD
(dashed lines) of the fitted secretion rates. (A) A673 tumor; and (B), HT1080
tumor. Results for fast-growing tumor are in Figure A1 in Appendix.
present freeVEGF concentration during twice-weekly injections of
VEGF Trap at 2.5 mg/kg (Figures 6A,B). The model estimates that
free VEGF in the body is first depleted before increasing slightly
before the next injection. Thus, the model can be used to under-
stand the effect of anti-VEGF agents on systemic and tissue levels
of VEGF.
In addition to using the model to estimate the concentration
of unbound VEGF, we have also determined the percentage of free
VEGF in the form of VEGF164 or VEGF165. The isoform secretion
ratio for VEGF164:VEGF120 in muscle is 92:8 and 90:10 in EC, and
the secretion ratio for VEGF165:VEGF121 in tumor cells is 50:50,
as described in the Section “Materials and Methods.” These ratios
determine the fraction of VEGF164 or VEGF165 in the compart-
ments; and, the fractions at which the isoforms are present change
with time and drug dose. Here, we consider a dosage of 2.5 mg/kg.
After the first anti-VEGF injection, the percentage of free mVEGF
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in the form of VEGF164 is∼90% in all compartments (Figure 6C,
left). The percentage of hVEGF in the form of VEGF165 in tumor
is slightly lower than the percentage of VEGF165 in normal tissue
and plasma (44–49%, as compared to 55%; Figure 6D). These
types of model predictions can aid in biomarker identification, as
the concentration of specific VEGF isoforms may predict tumors
that will respond to anti-VEGF treatment or other anti-angiogenic
therapies.
We also apply the model to investigate the total levels of cir-
culating VEGF in plasma. The soluble factors sVEGFR1 and α-2-
macroglobulin (α2M) bind to VEGF and contribute to circulating
levels of VEGF. Thus, total circulating VEGF is comprised of free
VEGF, VEGF bound to sVEGFR1, and α2M-bound VEGF (both
the native and active forms). VEGF bound to the VEGF Trap drug
is also included. We again allow the tumors to reach a volume of
100 mm3 before simulating twice-weekly injections of VEGF Trap
at varying doses. Before the first injection, the relative amounts of
free, sVEGFR1-bound, and α2M-bound circulating VEGF are 80,
4, and 16%, respectively. One day after the first injection of VEGF
Trap, the composition of the circulating VEGF changes, depending
on the drug dose (data not shown). If we consider a drug dose of
2.5 mg/kg, the relative amounts of free, sVEGFR1-bound, α2M-
bound, and VEGF Trap-bound VEGF are 0.6, 0.03, 5, and 94%,
respectively. Thus, the VEGF Trap displaces the soluble factors
bound to VEGF.
FIGURE 4 | Optimized VEGF secretion rates. The model parameters were
optimized to fit experimental data, and the values of normal, EC, and tumor
VEGF secretion rates were determined. The mean optimal secretion rates
and standard deviation of 20 optimization runs are shown. Results for
fast-growing tumors are in Figure A2 in Appendix.
DISCUSSION
We have developed a compartment model of VEGF distribution
in tumor-bearing mouse. The model incorporates tumor-specific
properties, including the rate of tumor growth and VEGF secre-
tion. We have used in vivo experimental data for the levels of free
and bound VEGF Trap in mice bearing human tumor xenografts
in order to predict the endogenous rate of VEGF secretion by
myocytes and ECs and compared them to the predicted secretion
rates in normal mice. We also predicted the rate at which cells from
different human tumor xenografts secrete VEGF. To our knowl-
edge, VEGF secretion rates can only be obtained from in vitro
experiments and cannot be directly measured in vivo; however,
VEGF concentrations that depend on the secretion rates can be
measured experimentally, although such interstitial measurements
are presently not available. Therefore, this work provides new
insight into VEGF levels in a pre-clinical in vivo model of cancer. In
addition, using the optimized model for tumor-bearing mice, we
have estimated the concentration of VEGF in the mouse following
administration of VEGF Trap, as well as the distribution of VEGF
in mice and circulating levels of VEGF Trap and the VEGF/VEGF
Trap complex. These results show that the concentration of free
VEGF in the tumor depends on the tumor-specific properties such
as the rate of tumor growth and the amount of VEGF secreted
by tumor cells. Lastly, we used the predicted level of VEGF Trap
and hVEGF/VEGF Trap complex to compare various dosages. The
model predicted that all hVEGF originating from the tumor is
neutralized at higher doses of the drug. This demonstrates an
important application of the model: to incorporate tumor-specific
properties and investigate the efficacy of different drug doses.
We used the two-compartment model to estimate VEGF secre-
tion rates, clearance of free and bound VEGF Trap, and the binding
affinity of VEGF Trap for normal mice. The value of binding affin-
ity of VEGF Trap estimated by the model is comparable to the
experimentally measured value (11). Additionally, the estimated
EC secretion is comparable to the experimentally determined value
of 0.028 molecules/cell/s (27). However, the predicted rate at which
muscle cells secrete VEGF is very low, and varying this parameter
over one order of magnitude does not significantly change the fit.
In contrast, EC secretion can be specified and changing this para-
meter drastically influences the fit to experimental data (results not
shown). These results may indicate that the rate of VEGF secre-
tion from muscle and ECs cannot be simultaneously estimated
using the available experimental data. That is, measurements of
free and bound VEGF Trap in plasma do not allow us to distin-
guish how muscle and ECs contribute to VEGF levels. Additional
experimental measurements such as interstitial levels of VEGF in
Table 2 | Estimated VEGF secretion rates from optimization of three-compartment model.
Tumor Baseline tumor growth profile* Fast growth profile
Normal EC Tumor Normal EC Tumor
A673 0.011±0.007 0.009±0.008 0.009±5×10−5 0.009±0.006 0.009±0.008 0.007±4×10−5
HT1080 0.007±0.006 0.008±0.008 0.023±3×10−4 0.007±0.006 0.008±0.008 0.017±3×10−5
*Secretion rate is given in molecules/cell/s. We report the mean±SD of the 20 optimization runs.
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FIGURE 5 | Predicted concentration profiles of systemic VEGFTrap.
The optimized model was applied to predict the time course of free VEGF
Trap (black), mouse VEGF bound to VEGF Trap (blue), and human VEGF
bound to VEGF Trap (red) in the mouse plasma after a single intravenous
injection of VEGF Trap at (A), 0.5 mg/kg; (B), 2.5 mg/kg; (C), 10 mg/kg; and
(D), 25 mg/kg in the A673 rhabdomyosarcoma human tumor xenograft. We
use the mean (solid lines) and standard deviation (dashed lines) of the
fitted secretion rates.
Table 3 | Estimated concentrations of free VEGF before VEGFTrap injection.
Tumor Range of free VEGF (pM)*
Mouse Human
Normal Plasma Tumor Normal Plasma Tumor
A673 0.17–1.47 0.04–0.61 0.002–0.02 5.03×10−5–5.30×10−5 1.18×10−3–1.20×10−3 0.49–0.50
HT1080 0.07–1.27 0.02–0.54 0.001–0.02 1.26×10−4–1.34×10−4 2.95×10−3–3.05×10−3 1.23–1.26
*Calculated using (mean±SD).
skeletal muscle are needed in order to predict VEGF secretion by
muscle fibers with confidence. Currently, interstitial VEGF con-
centrations are only available in human tissue (28–33); however,
similar studies in mice are of great interest.
We found that fitted parameters from normal mice were not
sufficient to match the levels of unbound and complexed VEGF
Trap in the model of tumor-bearing mice. We first attempted to
use the fitted parameters from the two-compartment model in the
model of tumor-bearing mice and use in vivo experimental data to
fit the rate of VEGF secretion from tumor cells. However, the model
overestimated the amount of VEGF Trap complexed with mVEGF
(results not shown). We are able to more closely fit the experi-
mental data for the tumor-bearing mice by optimizing the three-
compartment model independent of the optimized model for
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FIGURE 6 | Predicted concentration profiles of unbound VEGF. The
optimized model was applied to predict the time course of free VEGF
and the fraction of free VEGF in the form of VEGF164 or VEGF165 in
normal tissue (blue), plasma (red), and tumor (black) twice-weekly
injection of VEGF Trap at 2.5 mg/kg. (A) Free mVEGF; (B), free hVEGF;
(C), percentage of VEGF164; and (D), percentage of VEGF165 in the A673
rhabdomyosarcoma human tumor xenograft. We use the mean of the
fitted secretion rates.
normal mice. This indicates that endogenous VEGF secretion may
be different in normal and tumor-bearing mice (Tables 1 vs 2).
Experimental studies are needed to validate these results; however,
evidence shows that VEGF secretion is reduced following admin-
istration of VEGF Trap (34) or other anti-angiogenic therapies
(35–37).
The three-compartment model predicted that the in vivo
tumor VEGF secretion rates needed to fit experimental data are
lower than data obtained from in vitro measurements. In vitro
experimental measurements of the VEGF secretion rate vary
widely: 0.03–2.65 molecules/cell/s (38–41). We predicted that
human tumors secrete VEGF at rates range ranging from 0.007
to 0.023 molecules/cell/s. Interestingly, there is little variabil-
ity in the predicted tumor secretion rate, as indicated by the
small standard deviation (∼10−5 molecules/cell/s). Having exper-
imental measurements of the plasma concentration of VEGF
Trap bound to hVEGF (i.e., VEGF originating from the tumor)
enables us to predict the rate at which the tumor secretes VEGF
in vivo. In this way, xenograft models are preferable to syn-
geneic tumor models, in which VEGF derived from tumor and
other tissues are indistinguishable. Similarly, plasma measure-
ments in human patients would not be sufficient to specify tumor
VEGF. Thus, xenograft models provide unique insight into the
effects of anti-angiogenic therapies and are relevant to human
studies.
Tumor VEGF secretion is predicted to depend on the tumor
microenvironment. HT1080 tumors are predicted to secrete ∼2-
fold more VEGF than A673 tumors. Additionally, average- and
fast-growing tumors are predicted to secrete different amounts of
VEGF, where VEGF secretion in fast-growing tumors is slightly
lower than that of tumors that grow at an average rate. To our
knowledge, experimental data for VEGF secretion rates is limited
to in vitro measurements. Therefore, the ability to use the model
to determine the VEGF secretion from in vivo data and track and
quantify normal and tumor VEGF are important features of the
model.
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Using the optimized model, it is possible to estimate VEGF
concentrations in the mouse before and after VEGF Trap admin-
istration. In the model, we allowed the tumor to grow for 2 weeks
before the VEGF Trap injection. Just before the injection, the
estimated plasma VEGF levels are within the range of exper-
imental measurements in mouse of 0.3–1.4 pM (42, 43). The
model indicates that plasma VEGF depends on properties of
the tumor, such as volume, a result that is validated by exper-
imental evidence (44). Using the model, free VEGF in muscle
interstitium is predicted to range from 0.2 to 1.5 pM. To our
knowledge, interstitialVEGF in normal tissues has only been quan-
tified in human samples. Interstitial muscle VEGF in humans
ranges from 0.3 to 3 pM (28–33, 45). It is not clear how this
concentration range varies across species. However, since the
range of plasma VEGF measurements is similar between mice
and humans, where human plasma VEGF is measured to be 0.4–
3 pM (46), it is possible that interstitial VEGF is also comparable
in mice and humans. Thus, our model results and predictions
provide a framework to compare VEGF distribution in differ-
ent species and can be experimentally validated. Additionally,
we are able to predict the concentration of specific VEGF iso-
forms (i.e., the percentage of free VEGF in the form of VEGF164
or VEGF165, as compared to the shorter isoforms VEGF120 or
VEGF121). These results may be useful in identifying predictive
biomarkers for anti-VEGF treatment, where the level of VEGF121
is being evaluated as a biomarker (47, 48). We also applied the
model to estimate the relative contribution of sVEGFR1-bound
and α2M-bound VEGF to total circulating VEGF. The soluble fac-
tors compete with anti-VEGF agents; therefore, it is of interest to
investigate the effect of sVEGFR1 on the response to anti-VEGF
treatment. In this way, the model complements studies evaluat-
ing sVEGFR1 as a potential biomarker to predict resistance to
anti-VEGF treatment (49).
We can also compare the estimated levels of plasma VEGF gen-
erated by the model following administration of VEGF Trap with
experimental studies. In vivo studies of mice with breast tumor
xenografts indicate the plasma VEGF is reduced following VEGF
Trap treatment, particularly at the higher doses (34). Addition-
ally, Hoff and coworkers report that VEGF Trap is able to bind all
free VEGF 11 days after treatment in an experimental model of
rat glioma (50). These studies support the computational model
predictions. However, we are not aware of animal studies that
provide the time course of VEGF and VEGF/VEGF Trap concen-
tration, which is an important contribution of the model and
can complement pre-clinical studies that investigate the efficacy
of VEGF Trap.
We show that interstitial tumor VEGF levels depend on specific
properties of the tumor. To our knowledge, there are no experi-
mental measurements for interstitial tumor VEGF concentrations.
However, a sampling of available experimental measurements of
total VEGF in tumor tissue (free and bound VEGF, both intracel-
lular and extracellular) reveals a wide range of values, depending
on tumor type and size. File 1 in Supplementary Material shows a
compilation of measurements of tumor VEGF for various tumor
types. Experimental studies to measure free VEGF in tumor tissue
in mouse models would provide much needed quantitative data
to test and validate the model predictions presented here.
MODEL LIMITATIONS
We consider the model presented here to be a minimal model
that accurately reproduces experimental data, both qualitatively
and quantitatively. The model includes several assumptions, which
may be addressed as quantitative data become available. For exam-
ple, we assume the normal tissue is skeletal muscle, although other
tissues and organs secrete and contain VEGF (51), but are not
as well-characterized as muscle. We include two major VEGF
isoforms (VEGF120/VEGF121 and VEGF164/VEGF165); however,
other isoforms such as VEGF188/VEGF189 (52) and VEGFxxxb
(53, 54) also influence angiogenesis and may impact anti-VEGF
therapies. Recent studies also show that other VEGF ligands and
receptors contribute to angiogenesis (55–57),and the model can be
expanded in the future to include these molecular species. Addi-
tionally, although platelets contain large amounts of VEGF and
contribute to angiogenesis (58), we have not included them in
the model as the rate and conditions under which they secrete or
unload VEGF are unknown. We assume that as the tumor grows,
the relative proportions of interstitial space, vascular volume, and
tumor cells remain constant. However, experimental studies indi-
cate that these proportions should change as the tumor grows (59).
Finally, we have not included the effects of anti-VEGF treatment
on tumor volume or vascular permeability. Pre-clinical studies
show tumor growth inhibition and even regression of the tumor
following anti-angiogenic therapy that targets VEGF. We have per-
formed preliminary studies where the tumor volume is constant
after 1 week of anti-VEGF treatment since experimental studies
indicate that tumor growth is halted during 2 weeks of twice-
weekly VEGF Trap injections (34). We found that the predicted
tumor secretion rate is slightly larger when accounting for tumor
growth stagnation. This is because the tumor is smaller and con-
sists of fewer cells. Therefore, the amount of VEGF that must be
secreted on a per cell basis in order to obtain a certain level of VEGF
or VEGF/VEGF Trap complex is higher. Tumor permeability may
decrease with anti-angiogenic therapy, as the tumor normalizes
neovasculature and it begins to resemble normal vessels; how-
ever, we have not included that effect in the current model. In
a human model of VEGF transport and kinetics, we considered
“low” and “high” vascular permeability between the tumor and
blood (22). Interestingly, the model predicts that tumor VEGF can
increase above the pre-treatment level depending on properties of
the tumor microenvironment, even when tumor permeability is
high. Future computational studies may investigate the effect of
anti-VEGF treatment on tumor volume and vascular permeability
in greater detail.
CONCLUSION
The compartment model presented here provides a framework
to investigate the action of VEGF-targeting agents for particular
types of tumors. The physiologically based and experimentally val-
idated model, based on currently available animal data, predicted
the dynamic concentrations of molecular species and other biolog-
ical parameters that are difficult to quantify experimentally. Thus,
the model complements pre-clinical experiments, can aid in the
development of agents that target VEGF and inhibit angiogenesis,
and may be useful in evaluating biomarkers of anti-angiogenic
therapies. The model can be extended to human patients; this is
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particularly important since in 2012 aflibercept has been approved
to treat metastatic colorectal cancer in humans (60).
MATERIALS AND METHODS
COMPUTATIONAL MODEL
We have expanded the two-compartment model of VEGF dis-
tribution in the mouse (23) to include tumor tissue (“tumor
compartment”). The model is illustrated in Figure 7. Geometric
and kinetic parameters for the normal and blood compartments
have been fully detailed in (23). By simulating a human tumor
xenograft (tissue that grows from human cancer cells that have
been injected into the mouse), we also incorporate hVEGF iso-
forms and cross-species reactions between ligands and receptors.
Specifically, we include VEGF121 and VEGF165, which are secreted
by tumor cells. The human isoforms can bind to human receptors
present on tumor cells, as well as mouse receptors on endothelial
surfaces in the body (normal and tumor EC) and muscle fibers in
the normal compartment. Additionally, the mouse isoforms bind
to mouse receptors on muscle fibers and ECs and human recep-
tors on tumor cells. The model can also be adapted to simulate
mouse syngeneic tumors, where the tumor cells secrete VEGF120
and VEGF164; in this case, only mVEGF is present in the model. In
this work, however, we have focused on human tumors. The mol-
ecular interactions between VEGF and its receptors are illustrated
in Figure 8.
In addition to introducing the tumor compartment, we include
VEGF interactions with two soluble factors: soluble VEGFR1
(sVEGFR1) and α2M and introduce VEGF secretion by ECs. Sol-
uble VEGFR1 is secreted by ECs and transported throughout
the body, enabling it to interact with VEGF in all compart-
ments. The soluble factor α2M is present in two forms: native
and active (α2Mfast) (61). Both forms are present at high con-
centrations (nanomolar to micromolar levels) (62), and due to
their size (720 kDa MW), we assume that both forms are con-
fined to the blood compartment. The model predicts the levels
of free VEGF in the tissue interstitium and in plasma. These
soluble factors interfere with assays that measure VEGF concentra-
tion, making it difficult to distinguish between VEGF that is truly
free versus VEGF that is bound to trapping molecules (63). Both
sVEGFR1 and α2M can sequester VEGF and reduce the levels of
free VEGF. Therefore, it is important to include these factors in
the model.
We have also included VEGF secretion by ECs, as experimen-
tal studies demonstrate that EC are a source of VEGF (64, 65).
The luminal and abluminal endothelial surfaces secrete VEGF,
and luminal secretion is predicted to be a major determinant of
plasma VEGF. Due to EC secretion of VEGF, the compartments are
relatively autonomous, since the concentration of VEGF in each
compartment is determined primarily by the secretion rate in that
compartment, as well as the microenvironmental variables of the
compartment; however, transport between compartments is also
important.
The model is described by 258 non-linear ordinary differential
equations (ODEs), including 53 for the normal compartments,
126 for the blood, and 79 for the tumor compartment. In addi-
tion to the ODEs that describe how the species’ concentrations
vary with time, we include an equation for the tumor volume,
such that the model simulatesVEGF distribution in tumor-bearing
mice, immediately following inoculation of tumor cells. The initial
tumor volume is 10−6 cm3. A sampling of experimental data for
the volume of xenografts generated from MCF-7 and MDA-MB-
231 breast cancer cells (66–74) reveals various growth profiles. We
fit the data to exponential curves, accounting for a range of tumor
growth profiles (Figure 9). The growth curves fit experimental
data well, within the time scales used in the model (i.e., <6 weeks).
In cases where the model is run for longer times, different growth
FIGURE 7 |Three-compartment model ofVEGF. The model is comprised
of three-compartments: normal tissue, blood, and tumor. VEGF120 and
VEGF164 are secreted by myocytes in the normal tissue and by EC in all
compartments. Tumor cells secrete the human isoforms VEGF121 and
VEGF165. VEGF receptors (VEGFR1 and VEGFR2) and co-receptors (NRPs)
are localized on parenchymal and endothelial cells. Soluble VEGFR1 and
glycosaminoglycan (GAG) chains are present in the interstitial space.
Alpha-2-macroglobulin (α2M) is present in the blood. Molecular species
are transported between compartments via microvascular permeability
(k p) and lymphatic drainage (k L). All isoforms of unbound VEGF in the
tissue compartments are subject to proteolytic degradation (k deg) and are
removed from the blood via plasma clearance (cV).
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FIGURE 8 | Molecular interactions. The interactions of VEGF120 and VEGF164 are illustrated. VEGF121 is involved in the same binding reactions as VEGF120.
Similarly, the interactions for VEGF165 are the same as VEGF164. Differences in the interactions of VEGF120/121, as compared to VEGF164/165 are due to differential
exon splicing.
FIGURE 9 |Tumor growth profiles. We investigate the growth profiles of two categories of tumors: average- (blue) and fast-growing (green) tumors, based on
available experimental data. The data are fit to exponential curves, and the growth equations are given in the File 2 in Supplementary Material.
curves should be used in order to capture the full range of tumor
growth dynamics for the desired time scale. The complete set of
equations, chemical reactions, and glossary of terms are given in
File 2 in Supplementary Material.
SIMULATION OF ADMINISTRATION OF VEGF TRAP
Experimental studies utilize a subcutaneous injection of VEGF
Trap (“anti-VEGF”); however, the authors of the experimental
study state that the bioavailability of the drug is the same whether
injected subcutaneously or intravenously (12). The current model
does not include a subcutaneous compartment; therefore, we sim-
ulate an intravenous injection, which inherently assumes that all of
the drug appears in the blood. Injection lasts for 1 min (the dura-
tion does not affect the results, within limits) and is performed
once the tumor reaches a particular volume, according to experi-
mental methods described by Rudge et al. (12). Various doses of
VEGF Trap are used, as reported by Rudge and coworkers (12)
(0.5, 1, 2.5, 10, and 25 mg/kg).
SENSITIVITY ANALYSIS
In order to understand the impact of various parameters, we per-
form variance-based global sensitivity analyses using the eFAST
(75). The eFAST method estimates the sensitivity of model out-
puts (i.e.,VEGF concentration) with respect to variations in model
www.frontiersin.org July 2013 | Volume 3 | Article 196 | 11
Finley et al. VEGF Trap in tumor xenografts
parameters. The three-compartment model is run multiple times
with different parameter sets, where all parameters are varied from







where Aj and Bj are the Fourier coefficients of the cosine series
and sine series, respectively, for the frequency, j, associated with
the parameter i and include harmonics, p, of the base frequency.







The variances are used to estimate two indices that provide a
measure the sensitivity: first-order FAST indices, Si, and the total
FAST indices, STi . The first-order indices measure the local sensi-
tivity and do not account for interactions with other parameters:
Si = Di
Dtotal
The Total FAST indices measure of global sensitivity and
take into account second- and higher-order interactions between
parameters. STi are calculated by excluding the effects of the
complementary set of other parameters:
STi = 1− Dci
Dtotal
The eFAST method has been applied to systems biology models
(76), and our laboratory has previous used the method to inves-
tigate the sensitivity of VEGFR2 signaling (77). In this work, we
apply eFAST to investigate the sensitivity of steady state VEGF
concentrations with respect to kinetic parameters, transport para-
meters, and receptor expression levels. We use Simlab 2.2 from
Econometrics and Applied Statistics Unit EAS at the Joint Research
Centre of the European Commission to implement eFAST.
NUMERICAL IMPLEMENTATION
The model equations were implemented in MATLAB using the
SimBiology toolbox and were solved with the Sundials solver. The




The geometric parameters for the tumor compartment are sum-
marized in Table A1 in Appendix. The tumor cells are assumed to
have the same volume as the MCF-7 breast tumor cells, which
have a mean diameter of 12µm (78). A sphere of this diam-
eter would have a volume and surface area of 905µm3 and
452µm2, respectively. However, since tumor cells are not spher-
ical, we assume a dodecahedral cell of the same volume, which
has a surface area of 497µm3. The average luminal diameter of
capillaries in growing MCF-7 xenografts is 13.94µm (79), and
imaging of tumor vasculature supports this value (80). We assume
an EC thickness of 0.5µm, which would yield a cylindrical cross-
sectional area of 175µm2 and an outer perimeter of 46.9µm.
However, microvessels are not cylindrical. Therefore, to find the
true perimeter, we used a relationship between total perimeter
and total cross-sectional area in breast cancer capillaries, where the
increase in perimeter is 23% (81, 82), yielding a capillary perimeter
of 57.7µm.
The extracellular fluid volume fraction in the breast tumor
xenografts has been shown to range from 33 to 76% (78). Another
measurement reports the extracellular fluid volume in MCF-7
tumors to be 40% (83). We assume a value of 45%, which is divided
into interstitial space and intravascular space. We set the volume
fraction of intravascular space to be 10%, which is within the
range of available experimental data (84–86). Given the capillary
dimensions described above and an intravascular volume of 10%,
the capillary density is calculated to be 655 capillaries/mm2. Based
on a cell thickness of 0.5µm, the volume occupied by the ECs of
the microvessels is 1.5%. Cancer cells occupy the remaining tissue
volume of 53.5%. The volume fractions of microvessels and tumor
cells are then used to calculate the total surface area of all vessels
and tumor cells per unit volume of tissue: 378 cm2 EC surface/cm3
tissue and 2939 cm2 tumor cell surface/cm3 tissue.
The interstitial space is composed of extracellular matrix
(ECM), and basement membranes associated with the microves-
sels (endothelial basement membrane, EBM) and tumor cells
(parenchymal basement membrane, PBM). The thickness of the
basement membranes is assumed to be 50 and 30 nm, for the EBM
and PBM, respectively, yielding volume fractions of 0.0081 and
0.0015 cm3/cm3 tissue. The remaining volume of the interstitial
space is the ECM volume (34.04%).
Each region of the interstitial space can be represented as a
porous medium that contains a solid fraction composed primarily
of collagen that is unavailable to VEGF, and a fluid fraction that is
accessible to VEGF. The size of the pores further limits the volume
available for VEGF to diffuse. Therefore, the available volume in
the ECM and basement membranes is calculated as the product
of the volume, fluid fraction, and partition coefficient. The fluid
fraction is the non-collagen fraction and is calculated by using the
total collagen content in interstitial space. Given limited data for
this measurement, we used 5%, the same value as in our previous
models (24, 25, 87). The ratio of basement membrane collagen to
total body collagen is assumed to be 0.3, which yields 0.0482 for the
ratio of ECM collagen to total body collagen. The fluid fractions
are then 0.7 for the basement membranes and 0.9318 for the ECM.
The partition coefficient is the ratio of available fluid volume to
interstitial fluid volume. We take 0.9 for the partition coefficient for
the EBM (88), and the same value is used for the ECM and PBM,
as it is difficult to distinguish basement membranes and the ECM
(89). The available fluid volume for the ECM, EBM, and PBM are
therefore 0.2916, 9.720× 10−4, and 5.082× 10−3 cm3/cm3 tissue,
respectively.
Concentrations
Receptor densities and ECM binding site densities are listed in
Table A2 in Appendix. VEGFR1, VEGFR2, and NRP1 on the
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luminal and abluminal surfaces of diseased EC surfaces and on
tumor cells are based on quantitative flow cytometry measure-
ments in ECs isolated from tumor tissue, as described in (25). We
assume NRP2 surface concentration on tumor cells at the same
level as NRP1.
Kinetics
To our knowledge, there are no data for the kinetics of mVEGF
isoforms binding to glycosaminoglycan (GAG) chains or mouse
receptors or cross-reactions between human and mouse isoforms
and receptors. Therefore, we assume the kinetic rates for VEGF
binding to and dissociation from receptors, co-receptors, and GAG
chains in the ECM and basement membranes are the same as in
our previous papers, based on experimental data (23–25, 87) and
are given in Table A3 in Appendix. We use experimental data from
Papadopoulos (11) for the on and off rates of VEGF binding to
VEGF Trap.
Transport
Transport parameters for VEGF, anti-VEGF, and the VEGF/anti-
VEGF complex are listed in Table A4 in Appendix. Parameters
that govern transport between the normal and blood compart-
ments are the same as in our previous model (23). Here, we explain
specific transport parameters required for the addition of soluble
factors sVEGFR1 and α2M and the tumor compartment. As in the
previous model, myocytes are a source of VEGF and secrete the
VEGF isoforms VEGF120 and VEGF164 at a ratio of 8:92 (90, 91).
Additionally, tumor cells secrete VEGF into the tumor interstitium
at a ratio of 50:50 for VEGF121:VEGF165, based on experimental
quantification of mRNA isoform expression levels (92–96). Here,
we also consider VEGF secretion by EC. We set the secretion ratio
of VEGF120:VEGF164 by EC to be 10:90, similar to the isoform
ratio in muscle tissue, since to our knowledge, this ratio has not
been determined experimentally. Additionally, we assume normal
and tumor EC secrete the same amount of VEGF; tumor EC are
a small fraction of the total EC in the body, thus this assumption
should not affect VEGF distribution. The rates of VEGF secretion
by muscle fibers, EC, and tumor cells are determined by para-
meter optimization, fitting to experimental data from Rudge and
coworkers (12).
This expanded model includes soluble factors sVEGFR1 and
α2M. ECs are a source of sVEGFR1, and the rates of secre-
tion by normal EC was set to 6× 10−3 molecules/cell/s. Similar
to VEGF secretion, we assume that sVEGFR1 secretion rate is
the same for tumor EC. At steady state, the model estimated
the distribution of sVEGFR1 in the body to be 0.4, 2.1, and
0.04 pM in the normal, blood, and tumor compartments, respec-
tively. The level of sVEGFR1 in the plasma is within the range
of experimental measurements, which range from 1 to 10 pM
(97, 98). The clearance of α2M was set at 2.62× 10−3 min−1,
based on experimental measurements of the half-life, t 1/2 (99),
using ln(2)/t 1/2. The synthesis of α2M was then estimated from
mass balance at steady state, where the concentrations of native
and active α2M are 1.4µM (62) and 14 nM, respectively. We
assume that the concentration of active α2M is 100-fold lower
than that of the native form, based on experimental data for
humans (100–102).
Molecular species are removed from the system via two
mechanisms: plasma clearance and proteolytic degradation. The
values of these parameters are in Table A4 in Appendix.
For the normal endothelium, the permeability to sVEGFR1
and VEGF/sVEGFR1 is calculated using an empirical relation
between the Stokes–Einstein radius, aE, and molecular weight
[aE= 0.483× (MW)0.386], the corresponding theoretical macro-
molecular permeability-surface area product, PS (103), and the
capillary surface area, S. Taking microvascular permeability as
PS/S, and the calculated value is on the order of 10−8 cm/s, between
the normal and blood compartments. Since tumor vasculature is
more permeable than normal microvessels (104), we assume that
the microvascular permeability between the tumor and blood is
an order of magnitude higher than permeability between normal
and blood for both VEGF and the anti-VEGF or complex. There-
fore, the permeability to VEGF is 4× 10−7 and 3× 10−7 cm/s for
the anti-VEGF and VEGF/anti-VEGF complex. The permeability
to sVEGFR1 and VEGF bound to sVEGFR1 is 1.5× 10−7 cm/s.
Parameter estimation
The estimation of the VEGF secretion by muscle fibers, ECs,
and tumor cells was achieved using the “lsqnonlin” function in
MATLAB, as previously described (23). This algorithm solves the
non-linear least squares problem using the trust-region-reflective
optimization algorithm (105, 106), minimizing the weighted sum







Cexperimental, i − Csimulation, i(θ)
)]2
where Cexperimental, i is the ith experimentally measured plasma
concentration data point, C simulation, i(θ) is the ith simulated
plasma concentration at the corresponding time point, Wi is the
weight taken to be 1/Cexperimental, i , and n is the total number of
experimental measurements. The minimization is subject to the
upper and lower bounds of the free parameters, θ.
The two-compartment model was used to determine the rate
of VEGF secretion by muscle fibers and ECs (“normal” and “EC”
secretion, respectively), clearance of free and bound VEGF Trap,
dissociation constant of VEGF and VEGF Trap. These five free
parameters were fit to experimental data for the concentration
profiles of VEGF/VEGF Trap complex and unbound VEGF Trap
in mice at different doses of VEGF Trap (12), with a total of 58 data
points. The initial value of the secretion rates was generated within
the lower and upper bounds of 1.5× 10−6 and 2 molecules/cell/s,
respectively. The lower bound corresponds to 10 pg/ml and was
set based on the limit of detection of standard ELISA kits used to
measure (63). The half-life of VEGF Trap in mouse serum has been
reported as 72 h (107), which corresponds to a clearance rate of
1.6× 10−4 min−1, assuming clearance rate is equal to ln(2)/half-
life. The upper and lower bounds of the clearance rates were one
order of magnitude above and below this value, respectively. The
upper and lower bounds for the dissociation constant were set to
0.25 and 5 pM, based on experimental data (11, 12). The base-
line value of permeability of the normal tissue to VEGF Trap is
3× 10−8 cm/s, as described above, and the bounds were one order
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of magnitude above and below this value. The optimal parame-
ter values are reported as the mean and standard deviation of the
20 runs.
We used the three-compartment model to determine the rate
at which VEGF is secreted by tumor cells (“tumor secretion”) and
permeability of diseased tissue to free and complexed VEGF Trap.
Tumor secretion was optimized to fit experimental data for the sys-
temic VEGF Trap levels (free and complexed) reported by Rudge
et al. (12). Experimental data for two human tumor xenografts
(A673 rhabdomyosarcoma and HT1080 fibrosarcoma) were used
separately; the total number of data points was 11 for A673
tumors and 10 for HT1080 tumors. Twenty runs were performed
for each tumor, which either followed the average (baseline) or
fast growth profile. This yields two conditions for each tumor
type. The optimal secretion rates are reported as the mean and
standard deviation of the 20 runs and should be interpreted as
a range of values, where the values are dependent on the tumor
microenvironment, tumor type, and growth profile.
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APPENDIX
Table A1 | Geometric parameters.
Value Units Reference
CANCER CELLS
Tumor cell external diameter 12 µm Paran et al. (78)
Volume of one cell 905 µm3 Calculated (see manuscript)
Surface area of one cell 497 µm2 Calculated (see manuscript)
MICROVESSELS
Average luminal diameter 13.9 µm Schaefer et al. (79)
Endothelial cell thickness 0.5 µm Based on normal microvessels (108)
Average external diameter 14.9 µm Calculated (see manuscript)
Cross-sectional area of one vessel 175.3 µm2 Calculated (see manuscript)
Perimeter of one vessel 57.7 µm Calculated (see manuscript)
Capillary density 655 Capillaries/mm2 Calculated (see manuscript)
VOLUME FRACTIONS
Interstitial space 35.0% cm2/cm3 tissue Based on (78, 83)
Cancer cells 53.5% cm2/cm3 tissue Calculated (see manuscript)
Microvessels of which intravascular space 11.5% cm2/cm3 tissue Calculated (see manuscript)
10.0% cm2/cm3 tissue Based on (84–86)
SURFACE AREAS
Tumor cells 2939 cm2/cm3 tissue Calculated (see manuscript)
Microvessels 378 cm2/cm3 tissue Calculated (see manuscript)
BASEMENT MEMBRANES (BM)
Thickness of tumor cell BM 30 nm Based on (109)
Basement membrane volume (tumor cells) of which available to VEGF 0.00807 cm3/cm3 Calculated (see manuscript)
0.00508 cm3/cm3 tissue Calculated (see manuscript)
Thickness of microvessel BM 50 nm Based on (109)
Basement membrane volume (microvessels) of which available to VEGF 0.00154 cm3/cm3 tissue Calculated (see manuscript)
0.000972 cm3/cm3 tissue Calculated (see manuscript)
Extracellular matrix volume of which available to VEGF 0.3375 cm3/cm3 tissue Calculated (see manuscript)
0.2892 cm3/cm3 tissue Calculated (see manuscript)
Table A2 | Concentrations in tumor compartment.
Value Units
VEGFR1
Luminal EC 3750 Dimers/EC
Abluminal EC 3750 Dimers/EC
Tumor 1100 Dimers/TC
VEGFR2
Luminal EC 300 Dimers/EC
Abluminal EC 300 Dimers/EC
Tumor 550 Dimers/TC
NRP1
Luminal EC 39,748 Dimers/EC




ECM binding density 0.75 µM
EBM binding density 13 µM
PBM binding density 13 µM
EC, endothelial cell; TC, tumor cell.
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Table A3 | Kinetic parameters.
Value Unit Reference
VEGF BINDINGTO VEGFR1
kon 3×107 M−1 s−1 Mac Gabhann and Popel (87), Stefanini et al. (24)
koff 10−3 s−1 Mac Gabhann and Popel (87), Stefanini et al. (24)
K d 33 pM Mac Gabhann and Popel (87), Stefanini et al. (24)
VEGF BINDINGTO VEGFR2
kon 107 M−1 s−1 Mac Gabhann and Popel (87), Stefanini et al. (24)
koff 10−3 s−1 Mac Gabhann and Popel (87), Stefanini et al. (24)
K d 100 pM Mac Gabhann and Popel (87), Stefanini et al. (24)
VEGF BINDINGTO NRP1
kon 3.2×106 M−1 s−1 Mac Gabhann and Popel (87), Stefanini et al. (24)
koff 10−3 s−1 Mac Gabhann and Popel (87), Stefanini et al. (24)
K d 312.5 pM Mac Gabhann and Popel (87), Stefanini et al. (24)
VEGF BINDINGTO GAGs
kon 4.20×105 M−1 s−1 Mac Gabhann and Popel (87), Stefanini et al. (24)
koff 10−2 s−1 Mac Gabhann and Popel (87), Stefanini et al. (24)
K d 24 pM Mac Gabhann and Popel (87), Stefanini et al. (24)
COUPLING OF NRP1 AND VEGFR1
kc 1014 (mol/cm2)−1 s−1 Mac Gabhann and Popel (87), Stefanini et al. (24)
koff 10−2 s−1 Mac Gabhann and Popel (87), Stefanini et al. (24)
COUPLING OF NRP1 AND VEGFR2
kcV165R2, N1 3.1×1013 (mol/cm2)−1 s−1 Mac Gabhann and Popel (87), Stefanini et al. (24)
koffV165R2, N1 10−3 s−1 Mac Gabhann and Popel (87), Stefanini et al. (24)
kcV165N1, R2 1014 (mol/cm2)−1 s−1 Mac Gabhann and Popel (87), Stefanini et al. (24)
koffV165N1, R2 10−3 s−1 Mac Gabhann and Popel (87), Stefanini et al. (24)
VEGFR INTERNALIZATION
k int 2.8×10−4 s−1 Mac Gabhann and Popel (87), Stefanini et al. (24)
VEGF121 BINDINGTO ANTI-VEGF
kon 3.75×108 M−1 s−1 Calculated
koff 1.35×10−5 s−1 Papadopoulos et al. (11)
K d 0.36 pM Papadopoulos et al. (11)
VEGF165 BINDINGTO ANTI-VEGF
kon 4.10×107 M−1 s−1 Calculated
koff 2.01×10−5 s−1 Papadopoulos et al. (11)
K d 0.49 pM Papadopoulos et al. (11)
VEGF120 BINDINGTO ANTI-VEGF
kon 2.15×107 M−1 s−1 Calculated
koff 1.23×10−5 s−1 Papadopoulos et al. (11)
K d 0.572 pM Papadopoulos et al. (11)
VEGF164 BINDINGTO ANTI-VEGF
kon 2.80×107 M−1 s−1 Calculated
koff 1.64×10−5 s−1 Papadopoulos et al. (11)
K d 0.586 pM Papadopoulos et al. (11)
VEGF BINDINGTO α2M
kon 25 M−1 s−1 Calculated
koff 10−4 s−1 Assumed
K d 4.0 µM Bhattacharjee et al. (110)
VEGF BINDINGTO α2MFAST
kon 2.4×102 M−1 s−1 Calculated
koff 10−4 s−1 Assumed
K d 0.42 µM Bhattacharjee et al. (110)
(Continued)
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Table A3 | Continued
Value Unit Reference
sVEGFR1 BINDINGTO VEGF
kon 3×107 M−1 s−1 Assumed, based on VEGF binding to VEGFR1
koff 10−3 s−1 Assumed
K d 33 pM Assumed
sVEGFR1 BINDINGTO NRP1
kon 5.6×106 M−1 s−1 Calculated
koff 10−2 s−1 Assumed, based on VEGFR1 coupling to NRP1
K d 1.8 nM Fuh et al. (111)
sVEGFR1 BINDINGTO GAGs
kon 4.20×105 M−1 s−1 Assumed, based on VEGF165 binding to GAG
koff 10−2 s−1 Assumed
K d 24 pM Assumed
Table A4 |Transport parameters.
Value Unit Reference
PERMEABILITY BETWEEN NORMAL AND BLOOD
VEGF 4.0×10−8 cm/s Stefanini et al. (24)
Anti-VEGF and VEGF/anti-VEGF complex 3.0×10−8 cm/s Stefanini et al. (24)
Soluble VEGFR1 1.5×10−8 cm/s Calculated, see text
Soluble VEGFR1/VEGF complex 1.5×10−8 cm/s Calculated, see text
PERMEABILITY BETWEENTUMOR AND BLOOD
VEGF 4.0×10−7 cm/s Assumed, see text
Anti-VEGF and VEGF/anti-VEGF complex 3.0×10−7 cm/s Assumed, see text
Soluble VEGFR1 1.5×10−7 cm/s Assumed, see text
Soluble VEGFR1/VEGF complex 1.5×10−7 cm/s Assumed, see text
CLEARANCE
VEGF 2.3×10−1 min−1 Folkman (112)
Anti-VEGF 8.9×10−4 min−1 Yen et al. (23)
VEGF/anti-VEGF complex 2.8×10−4 min−1 Yen et al. (23)
Soluble VEGFR1 3.0×10−4 min−1 Wu et al. (113)
Soluble VEGFR1/VEGF complex 3.0×10−4 min−1 Wu et al. (113)
Alpha-2-macroglobulin (α2M) 2.6×10−3 min−1 Hudson et al. (99)
α2M/VEGF complex 2.6×10−3 min−1 Assumed, based on α2M
α2M/VEGF/anti-VEGF complex 2.6×10−3 min−1 Assumed, based on α2M
Activated alpha-2-macroglobulin (α2Mfast) 2.4×10−1 min−1 Imber and Pizzo (114)
α2M/VEGF complex 2.6×10−3 min−1 Assumed, based on α2Mfast
DEGRADATION
Soluble VEGFR1 1.2×10−2 min−1 Assumed based on VEGF
Soluble VEGFR1/VEGF complex 1.2×10−2 min−1 Assumed based on VEGF
SYNTHESIS
Alpha-2-macroglobulin 1.8×1010 Molecules/cm3 tissue/s Calculated, see text
Activated alpha-2-macroglobulin 1.6×1010 Molecules/cm3 tissue/s Calculated, see text
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FIGURE A1 | Predicted systemic VEGFTrap levels for fast-growing
tumors. The model predicts the plasma levels of free VEGF Trap (black
lines), mouse VEGF bound to VEGF Trap (blue lines), and human VEGF
bound to VEGF Trap (red lines) for fast-growing tumors. VEGF Trap was
administered twice per week for 2 weeks at doses of 0.5, 1, 2.5, 10, and 25
mg/kg. The simulated results are shown for the optimized model where the
secretion rates of VEGF by myocytes, EC, and tumor cells were fit to
experimental data (circles). We use the mean (solid lines) and 1 SD (dashed
lines) of the fitted secretion rates. (A) A673 tumor; and (B) HT1080 tumor.
FIGURE A2 | Optimized VEGF secretion rates. The model parameters
were optimized to fit experimental data, and the values of normal, EC, and
tumor VEGF secretion rates were determined. The mean optimal secretion
rates and standard deviation of 20 optimization runs for fast-growing
tumors are shown.
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